Executive Search and Leadership Development firm Borderless recently sponsored the Fourth Annual BioNJ CEO Summit, which brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s evolving market access and commercialization environment. Speakers explored issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.
“A clear message was that biopharmaceutical companies must develop a strategy early for Market Access and begin implementation in the pre-clinical phase of drug development. A sharp focus on pricing and transparency – currently under public scrutiny in the US – reinforces our observation that the increased demand and competition for skilled Market Access professionals will not abate,” explains Borderless Consultant Andrei Costache.
BioNJ, The Gateway to Health, is a network of more than 400 Members, including Borderless, representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
